Overview
To access this data, please log into DSS and submit an application.
Within the application, add this dataset (accession NG00185) in the “Choose a Dataset” section.
Once approved, you will be able to log in and access the data within the DARM portal.
Description
As part of the CATSLife project, saliva, buffy coat and peripheral blood mononuclear cells (PBMCs) were isolated from 89 CATSLife1 participants. Methylation array data were collected using Illumina EPIC methylation array.
Sample Summary per Data Type
| Sample Set | Accession | Data Type | Number of Samples |
|---|---|---|---|
| DNA methylation in saliva, buffy coat and PBMC samples in CATSLife | snd10140 | DNA Methylation | 258 |
Available Filesets
| Name | Accession | Latest Release | Description |
|---|---|---|---|
| CATSLife Saliva, Buffy Coat, PBMC Methylation Data | fsa000167 | NG00185.v1 | CATSLife Saliva, Buffy Coat, PBMC Methylation Data |
View the File Manifest for a full list of files released in this dataset.
Participant Information
For a breakdown of the study population characteristics, navigate to the individual sample sets below.
| Sample Set | Accession Number | Number of Participants | Number of Samples |
|---|---|---|---|
| DNA methylation in saliva, buffy coat and PBMC samples in CATSLife | snd10140 | 89 | 258 |
Related Studies
-
The Colorado Adoption/Twin Study of Lifespan behavioral development & cognitive aging (CATSLife) aims are to: conduct a genetically sensitive study of individual differences in behavioral and cognitive change at the…
Cohorts
| Cohort | Number of Participants | Number of Samples |
|---|---|---|
| Colorado Adoption/Twin Study of Lifespan behavioral development & cognitive aging (CATSLife) | 89 | 258 |
Consent Levels
| Consent Level | Number of Participants | Number of Samples |
|---|---|---|
| HMB-IRB-PUB-NPU-MDS | 89 | 258 |
Visit the Data Use Limitations page for definitions of the consent levels above.
Acknowledgement
Acknowledgment statement for any data distributed by NIAGADS:
Data for this study were prepared, archived, and distributed by the National Institute on Aging Alzheimer's Disease Data Storage Site (NIAGADS) at the University of Pennsylvania (U24-AG041689), funded by the National Institute on Aging.
Use the study-specific acknowledgement statements below (as applicable):
For investigators using any data from this dataset:
Please cite/reference the use of NIAGADS data by including the accession NG00185.
For investigators using The Colorado Adoption/Twin Study of Lifespan behavioral development & cognitive aging (CATSLife) (sa000046) data:
The Colorado Adoption/Twin Study of Lifespan behavioral development & cognitive aging (CATSLife) project is supported by the National Institute on Aging (grant number NIA R01AG046938) and conducted at the University of Colorado Boulder.
Publications
- Bruellman R. Differential DNA methylation clock ages across buffy coat (BC), peripheral blood mononuclear cells (PBMC), and saliva in individuals in early-to-mid adulthood. Epigenetics. 2026 Dec 31. PubMed link
Approved Users
- Investigator:Haines, JonathanInstitution:Case Western Reserve UniversityProject Title:Date of Initial Approval:October 30, 2026Current Status:ApprovedPublications:None ReportedResearch Use Statements:Show statementsTechnical Research Use Statement:Objectives: The overall goal of the planned analyses for ADAPTT is to better characterize the known genetic loci that are associated with AD/ADRD to identify the most probable functional elements responsible for the association. Most of these known associations have not been assigned to specific genes or functional variants. We plan to analyze DNA variation from SNP array, whole exome and whole genome sequence data generated from participants that span the spectrum of dementia (with a focus on Alzheimer disease (AD) but also including MCI and related dementias [ADRD]) and participants without dementia (typically considered “controls”). Study Design: We will evaluate these known loci, including the many genes underlying these associations, by integrating available genetic data, genomic data, in silico annotations, and multi-omic data using multiple different computational approaches. Our approaches will be sensitive to the different study designs of the contributing datasets (e.g. cohort studies, case-control studies, family-based studies). We will also examine a small number of these loci, prioritized by our analyses, using molecular genomic methods to better characterize the molecular mechanisms underlying the associations. Collaboration: This is a collaboration with Drs. Martin, Pericak-Vance, and Vance at the University of Miami.Non-Technical Research Use Statement:We are attempting to identify the inherited elements that contribute to Alzheimer disease risk. To do this we will analyze DNA sequence data from participants with Alzheimer disease and related dementias along with subjects who are cognitively normal. There are many known regions of the human genome that are associated with AD/ADRD risk, but the actual DNA sequence variations that are responsible for those associations remain unknown. Our goal is to use statistical and computer methods to identify the underlying responsible variations. For a small number of these, we will directly examine the biological mechanisms that help explain how those variations impact AD/ADRD.
- Investigator:Higgins-Chen, AlbertInstitution:Yale UniversityProject Title:Date of Initial Approval:October 29, 2025Current Status:ApprovedPublications:Show publications (1)
- Sehgal R. Responsiveness of epigenetic aging biomarkers to longevity interventions in humans. Nature medicine. 2026 Sep. PubMed link
Research Use Statements:Show statementsTechnical Research Use Statement:The TranslAGE research project aims to evaluate and optimize DNA methylation (DNAm)-based aging biomarkers for geroscience clinical trials. We will benchmark existing biomarkers to identify those that are: (1) responsive to aging interventions, (2) prognostic for age-related diseases and outcomes, and (3) stable over time without intervention. This will guide the development of next-generation biomarkers. Study Design: We will analyze DNAm and phenotypic data from the Health and Retirement Study (HRS), evaluating how various DNAm biomarkers relate to mortality, disease, and physical and cognitive function. All pipelines and variable names will be harmonized with other major studies, including the Baltimore Longitudinal Study of Aging (BLSA) and Framingham Heart Study, enabling cross-study comparison. Analysis Plan: 1. Data Harmonization: Core variables (age, sex, death, follow-up time) will be standardized using a common data dictionary. 2. Biomarker Computation: Multiple DNAm biomarkers will be calculated using https://github.com/HigginsChenLab/methylCIPHER and Z-scored for comparability. 3. Model Fitting: Cox models for mortality and disease onset, Logistic regression for incident disease, Linear models for continuous traits like cognition, BMI, gait speed. 4. Performance Evaluation: Predictive performance will be assessed using hazard ratios, concordance index (C-index), and AUCs. Biomarkers will be ranked across domains, and visualizations will summarize associations. 5. Cross-Study Integration: Summary statistics will be compared with those from external cohorts, intervention studies (e.g., effect sizes), and test-retest reliability datasets (e.g., intraclass correlation) 6. Composite Development: Top biomarkers with strong prognostic power, responsiveness, and stability will be combined into a composite score. Novel mortality, morbidity, and frailty predictors will be trained in external datasets and validated in HRS. Planned collaborations: Sofiya Milman at Albert Einstein College of Medicine (relating DNAm biomarkers to frailty), Jessica Lasky-Su at Brigham and Women’s Hospital (relating DNAm proxies of serum proteins and metabolites to aging outcomes).Non-Technical Research Use Statement:The TranslAGE knowledgebase aims to improve how we measure biological aging, helping scientists evaluate new treatments that target the aging process. We will use DNA methylation from these and other studies to identify biomarkers that predict future health, respond to anti-aging therapies, and remain stable over time. We will calculate many different biological age scores from blood samples and test how well each one predicts outcomes like memory, physical ability, disease, and mortality. We will combine this information with results from other studies to identify the best scores that not only predict future age-related disease, but are also responsive to treatments intended to prevent future disease. We will also use insights from this study to develop better biological age scores that may eventually be used to assess whether interventions are successfully modifying the aging process to promote healthier, longer lives. - Investigator:Maier, AndreaInstitution:National University of SingaporeDate of Initial Approval:July 30, 2026Current Status:ApprovedPublications:None ReportedResearch Use Statements:Show statementsTechnical Research Use Statement:This project will develop DNA methylation (DNAm)-based surrogates of clinical, functional, metabolomic, proteomic and other molecular biomarkers, and integrate them into interpretable physiological system- and disease-specific predictors of biological ageing. The objectives are to improve prediction of mortality, frailty, disability, cognitive decline, ADRD/dementia and other age-related diseases, and to identify pathways underlying multisystem ageing. The study will use an observational cohort design. HRS will serve as the primary training dataset because it links DNAm profiles with clinical, functional, genetic and longitudinal health data. Other DNAm datasets will be used as external validation cohorts to assess generalisability across populations and study settings. Analyses will include epigenome-wide association and differential methylation analyses to identify CpGs associated with target biomarkers and ageing-related phenotypes. Penalised regression, primarily elastic net with nested cross-validation, will be used to train DNAm surrogate models. Other machine-learning methods may be explored where appropriate. DNAm surrogates will be grouped into physiological systems or disease domains using biological annotation, clustering and model-based approaches. The resulting DNAm proxies and integrated scores will be evaluated in association with mortality, multimorbidity, frailty, disability, functional performance, cognitive performance, cognitive decline, ADRD/dementia and other age-related diseases. Where genotype data are available, genome-wide variants and polygenic risk scores will be assessed in relation to DNAm surrogates and ageing-related phenotypes to evaluate genetic contributions to biological ageing and disease susceptibility. Restricted data will be analysed only within approved secure environments. Exported results will be aggregate only, such as regression coefficients, hazard ratios, odds ratios, summary statistics and model performance metrics. No individual-level data, direct identifiers or small-cell outputs will be exported. Planned collaborators include Prof Andrea B. Maier and researchers at the Academy for Healthy Longevity, NUS.Non-Technical Research Use Statement:Ageing affects many parts of the body, but current biological ageing tests do not fully capture this complexity. This project aims to develop new DNA methylation-based measures that reflect different aspects of health, including clinical markers, physical function, metabolism and age-related diseases. DNA methylation is a chemical mark on DNA that can provide information about biological ageing. The Health and Retirement Study will be used as the main dataset to develop these measures because it includes DNA methylation data linked with long-term health information. Other DNA methylation datasets will be used to test whether the measures work well in different populations. The goal is to create more accurate and interpretable tools for studying ageing, predicting risks such as frailty, disability, dementia and mortality, and understanding how different body systems age together. Findings will be reported only as summary results, with no release of individual-level participant data.
- Investigator:Seshadri, SudhaInstitution:Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, TXDate of Initial Approval:October 14, 2020Current Status:ApprovedPublications:Show publications (9)
- Bouzid H. Clonal hematopoiesis is associated with protection from Alzheimer's disease. Nature medicine. 2023 Jul. PubMed link
- Horimoto ARVR. Admixture mapping implicates 13q33.3 as ancestry-of-origin locus for Alzheimer disease in Hispanic and Latino populations. HGG advances. 2023 Jul 13. PubMed link
- Tin A. Identification of circulating proteins associated with general cognitive function among middle-aged and older adults. Communications biology. 2023 Nov 3. PubMed link
- Wang Y. Key variants via the Alzheimer's Disease Sequencing Project whole genome sequence data. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024 May. PubMed link
- Lee WP. Association of common and rare variants with Alzheimer's disease in more than 13,000 diverse individuals with whole-genome sequencing from the Alzheimer's Disease Sequencing Project. Alzheimer's & dementia : the journal of the Alzheimer's Association. 2024 Dec. PubMed link
- Wang D. Frequency of variants in Mendelian Alzheimer's disease genes within the Alzheimer's Disease Sequencing Project. Journal of Alzheimer's disease : JAD. 2025 Apr. PubMed link
- Wang D. Application of the STAAR framework in detecting rare variant associations with Alzheimer disease and related dementias: Insights and implications. HGG advances. 2026 Apr 9. PubMed link
- Contreras AG. Genetic modifiers of APOE-ε4-associated cognitive decline. Nature communications. 2026 Feb 20. PubMed link
- Peloso GM. Whole genome sequencing analysis of over 3500 individuals dementia-free over 85 years old. Journal of Alzheimer's disease : JAD. 2026 Jun. PubMed link
Research Use Statements:Show statementsTechnical Research Use Statement:Objective: Utilize ADSP data sets to identify genes & specific genetic variants that confer risk for or protection from Alzheimer disease. Aim 1: Using combined WGS/WES across the ADSP Discovery, Disc-Ext, and FUS Phases, including single nucleotide variants, small insertion/deletions, and structural variants. We will: Aim 1a. Perform whole genome single variant and rare variant case/control association analyses of AD using ADSP and other available data; Aim 1b. Target protective variant identification via association analysis using selected controls within the ADSP data and performing meta analysis across association results based on selected controls from non-ADSP data sets. Aim 1c. Perform endophenotype analyses including cognitive function measures, hippocampal volume and circulation beta-amyloid ADSP data in subjects for which these measures are available. Meta analysis will be conducted across ADSP and non-ADSP analysis results. Aim 2: To leverage ethnically-diverse and admixed populations to identify AD variants we will: Aim 2a. Estimate and account for global and local ancestry in all analyses; Aim 2b. Perform admixture mapping in samples of admixed ancestry; and Aim 2c. Perform ethnicity-specific and trans-ethnic meta-analyses. Aim 3: To identify putative therapeutic targets through functional characterization of genes and networks via bioinformatics, integrative omics analyses. We will: Aim 3a. Annotate variants with their functional consequences using bioinformatic tools and publicly available “omics” data. Aim 3b. Prioritize results, group variants with shared function, and identify key genes functionally related to AD via weighted association analyses and network approaches. Analyses will be performed in coordination with the following PIs. Coordination will involve sharing expertise, analysis plans or analysis results. No individual level data will be shared across institutions. Philip De Jager, Columbia University; Eric Boerwinkle & Myriam Fornage, UT Health Science Center at Houston; Sudha Seshadri, UT Health Science Center at San Antonio; Ellen Wijsman, University of Washington; William Salerno, Baylor College of Medicine.Non-Technical Research Use Statement:This proposal seeks to analyze existing genetic sequencing data generated as part of the Alzheimer’s Disease Sequencing Project (ADSP) including the ADSP Follow-up Study (FUS) with the goal of identifying genes and specific changes within those genes that either confer risk for Alzheimer’s disease or provide protection from Alzheimer’s disease. Analytic challenges include analysis of whole genome sequencing data, appropriately accounting for population structure across European ancestry, Hispanic, and African American participants, and interpreting results in the context of other genomic data available. - Investigator:Zhou, WeichenInstitution:University of MichiganProject Title:Date of Initial Approval:March 27, 2023Current Status:ApprovedPublications:Show publications (2)
- Zhou W. Somatic nuclear mitochondrial DNA insertions are prevalent in the human brain and accumulate over time in fibroblasts. PLoS biology. 2024 Aug. PubMed link
- Zhou W. A personalized multi-platform assessment of somatic mosaicism in the human frontal cortex. bioRxiv : the preprint server for biology. 2025 Oct 11. PubMed link
Research Use Statements:Show statementsTechnical Research Use Statement:Explore somatic transposable elements and their Alzheimer's disease-related patterns using genomic and phenotypic data from large cohorts: In order to explore the impact of the transposable element in Alzheimer's disease, we propose to conduct a systematic survey in the available large cohorts. The ADSP dataset in NIAGAlzheimer's diseaseS (Accession No. NG00067) includes 16,906 whole-genome sequences and 20,504 whole-exome sequences for case-control and family-based studies of Alzheimer's disease from diverse populations, which is a perfect resource to leverage in this project. Under the support of the Michigan Alzheimer's Disease Center, we will request to access NIAGADS. To detect somatic transposable elements in the ADSP dataset, we will employ established computational pipelines to resolve the transposable elements in the sequencing data, MELT and xTEA for WGS and SCRAMble for WES, respectively. Parameters in these tools, for instance, the calling threshold of supporting reads, will be adjusted accordingly to cooperate with the detection of somatic transposable elements in cells at low frequency. To exclude potential germline transposable elements, we will leverage a master set of polymorphic transposable elements from diverse populations, which are based on our previous projects at the Human Genome Structural Variation Consortium, and the case-control information provided by ADSP. We aim to summarize a spectrum of somatic transposable elements that would be Alzheimer's disease-relevant along with various clinical and phenotypic information. To build Alzheimer's disease-related genetic patterns we will implement Mutect2 (GATK) and Strelka2 to discover SNVs from WGS and WES data and link them with transposable elements in the same haplotype. After obtaining this set of patterns, we will collect phenotypic information from the ADSP dataset to conduct family-based associated analysis and gene-burden analysis. RegulomeDB will be used to annotate the effects of non-coding functional impact and regulatory changes for these Alzheimer's disease-related patterns.Non-Technical Research Use Statement:It seeks to explore the connection between the somatic transposable elements in the human genome and Alzheimer’s disease and related dementias. It will leverage large-scale datasets to extensively explore the genome-wide transposable elements and then stratify Alzheimer’s disease-relevant ones by using the rich clinical information from the cohorts. Further analysis pipelines will be built based on the results of the proposed project to investigate the functional impact of these transposable elements on Alzheimer’s disease and would improve the understanding of genetic causes of Alzheimer’s disease and related dementias.
Total number of participants: 89
| White | 78 |
| NA | 11 |
-
221 (1.1%)
-
2311 (12.4%)
-
241 (1.1%)
-
3353 (59.6%)
-
3421 (23.6%)
-
441 (1.1%)
-
NA1 (1.1%)
| NA | ||
|---|---|---|
| Unknown | 89 | 100.0% |